The content on this site is intended for healthcare professionals only
Dr Geraldo Alves speaks to ecancer at the 2019 ecancer-Oncosalud Symposium of Molecular Clinical Oncology in Peru about the main advances in the treatment of peritoneal metastases in gastric cancer.
He reports the results from one study in which patients treated with a combination of hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery survived longer, compared to patients treated with cytoreductive surgery alone.
Dr Alves also describes further trials, including the
PERISCOPE II and GASTRIPEC studies, that are investigating the effect of perioperative chemotherapy plus HIPEC in high-risk patients.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Durable responses in aRCC, how do we optimise treatment?
Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC
Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
The parotid gland; an unusual site of colorectal cancer metastasis
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
The role of multidisciplinary tumour board in managing stage 3 lung cancer
